



VirtualScopics  
500 Linden Oaks  
Rochester, New York 14625

## **VirtualScopics' Dr. Edward Ashton to Speak at Upcoming ISMRM Conference**

*Chief Scientific Officer to Lecture on the Advantages of Quantitative Imaging*

ROCHESTER, NY – April 22, 2010 - VirtualScopics, Inc. (NASDAQ: VSCP), a leading provider of quantitative imaging for clinical trials, announced today that its Chief Scientific Officer, Dr. Edward Ashton, will be an invited lecturer at the upcoming International Society for Magnetic Resonance in Medicine (ISMRM) Annual Meeting in Stockholm, Sweden.

Dr. Ashton's lecture, entitled *Quantitative MR in Multi-Center Clinical Trials*, is scheduled for Wednesday, May 5, 2010. The lecture will be an extension of Dr. Ashton's recently published article in the February issue of the *Journal of Magnetic Resonance Imaging (JMRI)*. Dr. Ashton will review the benefits of using quantitative MR imaging in clinical trials, and explore the challenges of developing and deploying an MR protocol across numerous and varied MR systems and software versions.

Dr. Ashton will be speaking on two other occasions during the conference. He will be a member of the MR in Drug Research study group discussing the use of MRI for oncology drug development. Additionally, Dr. Ashton will be presenting a poster entitled *Comparison of Diffusion and DCE-MRI as Markers for Response to Therapy in Hepatocellular Cancer Patients*.

International Society for Magnetic Resonance in Medicine is an international, nonprofit, scientific association whose purpose is to promote communication, research, development, and applications in the field of magnetic resonance in medicine. The ISMRM Annual Meeting is considered to be among the most prestigious conferences in the medical imaging industry.

### **About VirtualScopics, Inc**

VirtualScopics, Inc. is a leading provider of imaging solutions to accelerate drug and medical device development. VirtualScopics has developed a robust software platform for analysis and modeling of both structural and functional medical images. In combination with VirtualScopics' industry-leading experience and expertise in advanced imaging biomarker measurement, this platform provides a uniquely clear window into the biological activity of drugs and devices in clinical trial patients, allowing sponsors to make better decisions faster. For more information about VirtualScopics, visit [www.virtualscopics.com](http://www.virtualscopics.com)

####

### **Forward-Looking Statements**

The statements contained in this press release that are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and

Section 21E of the Securities Exchange Act of 1934, as amended, and are intended to be covered by the safe harbors created thereby. These forward-looking statements include, but are not limited to, statements regarding the expected benefits of the Company's investment in infrastructure and new customer contract signings and awards and/or statements preceded by, followed by or that include the words "believes," "could," "expects," "anticipates," "estimates," "intends," "plans," "projects," "seeks," or similar expressions. Forward-looking statements deal with the Company's current plans, intentions, beliefs and expectations. Investors are cautioned that all forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Many of these risks and uncertainties are discussed in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2009 filed with the Securities and Exchange Commission (the "SEC"), and in any subsequent reports filed with the SEC, all of which are available at the SEC's website at [www.sec.gov](http://www.sec.gov). These include without limitation: the risk of cancellation or delay of customer contracts or specifically as it relates to contract awards, the risk that they may not get signed. Other risks include the company's dependence on its largest customers and risks of contract performance, protection of our intellectual property and the risks of infringement of the intellectual property rights of others. All forward-looking statements speak only as of the date of this press release and the Company undertakes no obligation to update such forward-looking statements.

**Company Contact:**

Molly Henderson  
Chief Business and Financial Officer  
500 Linden Oaks  
Rochester, New York 14625  
(585)249.6231